Results 81 to 90 of about 6,428 (208)

Repeated Tetrahydrocannabinol Injections Induce Tolerance but Do Not Disrupt Ongoing Behaviour Upon Withdrawal in Male and Female Rats With Inflammatory Pain

European Journal of Pain, Volume 30, Issue 5, May 2026.
ABSTRACT Background Many people use cannabis to self‐medicate for pain. Little is known about the impact of pain on tolerance and spontaneous withdrawal to delta‐9‐tetrahydrocannabinal (THC), the primary psychoactive compound in cannabis. Our previous research with the opioid morphine suggests persistent pain will increase the magnitude and duration of
Michael M. Morgan, Christa M. Hickey
wiley   +1 more source

Exploring Linalool‐Based Phytotherapy for Excitatory/Inhibitory Imbalance in Alzheimer's Disease: A Review of Lavender and Cannabis Therapeutic Effects on Sleep, Seizures, and Cognition

Phytotherapy Research, Volume 40, Issue 5, Page 2604-2631, May 2026.
Schematic overview of the proposed neuromodulatory actions of linalool in Alzheimer's disease. Through multi‐target effects on oxidative stress, amyloid aggregation, GABAergic and glutamatergic signaling, linalool may restore excitatory/inhibitory balance.
Ilaria Piccialli, Giovanni Roviello, Giorgia Magliocca, Emilia Esposito, Anna Pannaccione   +4 more
wiley   +1 more source

Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

, 2005
BACKGROUND: Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients.
Jordi Salas ; Jean-Pierre Després; Alain Golay; Lars Sjöström; Rimonabant in Obesity
core  

The cannabinoid CB1 receptor antagonists rimonabant (SR141716) and AM251 directly potentiate GABA(A) receptors

, 2012
Rimonabant (SR141716) and the structurally related AM251 are widely used in pharmacological experiments as selective cannabinoid receptor CB(1) antagonists / inverse agonists. Concentrations of 0.5-10 µM are usually applied in in vitro experiments.
Baur, R, R Baur, E Sigel, Gertsch, J, J Gertsch, Sigel, E   +5 more
core   +1 more source

Acute rimonabant treatment promotes protein synthesis in C2C12 myotubes through a CB1‐independent mechanism

, 2020
International audienceSarcopenia is an age-related loss of muscle mass associated with changes in skeletal muscle protein homeostasis due to lipid accumulation and anabolic resistance; changes that are also commonly described in obesity.
Kristell Combe, Lanchais, Kassandra, Stéphane Walrand, Walrand, Stéphane, Kassandra Lanchais, Combe, Kristell, Loïc Van Den Berghe, Le Bacquer, Olivier, van den Berghe, Loïc, Olivier Le Bacquer   +9 more
core   +1 more source

Cannabinoid type I receptor antagonists (rimonabant) for smoking cessation [PDF]

, 2007
Rimonabant is a selective type 1 cannabinoid ( CB1) receptor antagonist. It may assist with smoking cessation by restoring the balance of the endocannabinoid system, which can be disrupted by prolonged use of nicotine.
Ussher, M, Michael H Ussher, K Cahill, Kate Cahill, Cahill, K, M Ussher   +5 more
core   +1 more source

Modern drugs for obesity and metabolic syndrome treatment (Review)

Сеченовский вестник, 2016
The article reviews modern anti-obesity drugs to identify new trends in effective and safe risk factors reduction (diabetes, cardiovascular and musculoskeletal diseases, cancer).
M. L. Maximov, O. V. Dralova, V. G. Kukes, V. N. Chubarev, V. V. Tarasov   +4 more
doaj  

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss

BMC Endocrine Disorders, 2017
Background Evidence suggests that endocannabinoid system activation through the cannabinoid receptor 1 (CB1) is associated with enhanced liver injury, and CB1 antagonism may be beneficial.
Alison J. Dawson, Eric S. Kilpatrick, Anne-Marie Coady, Abeer M. M. Elshewehy, Youssra Dakroury, Lina Ahmed, Stephen L. Atkin, Thozhukat Sathyapalan   +7 more
doaj   +1 more source

Rimonabant: From RIO to Ban

, 2020
Endocannabinoid antagonism as a treatment for obesity and the metabolic syndrome became a hugely anticipated area of pharmacology at the start of the century.
Amir H Sam, Mohammad A Ghatei, Victoria Salem   +2 more
core  

Rimonabant improves hepatic steatosis in OLETF rats.

, 2018
(A) Representative hematoxylin and eosin-stained liver sections (scale bars, 200 μm; magnification, 200 X). (B) NAFLD activity score. Representative images of Masson’s trichrome staining (C; scale bars, 100 μm; magnification, 400 X) and fibrosis score (D)
Hyekyung Yang (2461081), Cheol-Young Park (110920), Da Hyun Lee (3614552), Soo Han Bae (2850584), Dae-Hee Kim (3179325), Eugene Chang (180832)   +5 more
core   +1 more source